Several new biologic agents targeting IL23/Th17 axis, such as risankizumab, have been developed for the treatment of psoriasis. The aim of the present study was to analyze the efficacy and safety of risankizumab in patients with moderate-to-severe psoriasis over a 52-week period. A multicentric retrospective study was conducted in patients who initiated risankizumab between July 2019 and December 2020. Psoriasis Area and Severity Index-PASI was measured at baseline and after 4, 16, 28 and 52 weeks. Clinical responses were evaluated by PASI75, PASI90 and PASI100 at the same timepoints. Potential safety issues and adverse events (AEs) were collected. Univariable and multivariable logistic regressions were performed for variables predicting clinical response. One hundred and twelve patients with psoriasis were included. PASI90 response was achieved by 17.86% of patients at week 4, 72.22% at week 16, 91.0% at week 28 and 95.24% at week 52 (as observed analysis). No associations between the considered variables and the efficacy endpoints were retrieved, influence of variables such as Body Mass Index (BMI), baseline PASI or previous biologics were not shown. No serious safety issues or discontinuations related to adverse events were reported. Risankizumab showed high efficacy and a favorable safety profile, regardless of patient- and disease-related factors.

Caldarola, G., Zangrilli, A., Bernardini, N., Bavetta, M., De Simone, C., Graceffa, D., et al. (2022). Risankizumab for the treatment of moderate-to-severe psoriasis: A multicenter, retrospective, 1 year real-life study. DERMATOLOGIC THERAPY, 35(6), e15489 [10.1111/dth.15489].

Risankizumab for the treatment of moderate-to-severe psoriasis: A multicenter, retrospective, 1 year real-life study

Bianchi, Luca
2022-06

Abstract

Several new biologic agents targeting IL23/Th17 axis, such as risankizumab, have been developed for the treatment of psoriasis. The aim of the present study was to analyze the efficacy and safety of risankizumab in patients with moderate-to-severe psoriasis over a 52-week period. A multicentric retrospective study was conducted in patients who initiated risankizumab between July 2019 and December 2020. Psoriasis Area and Severity Index-PASI was measured at baseline and after 4, 16, 28 and 52 weeks. Clinical responses were evaluated by PASI75, PASI90 and PASI100 at the same timepoints. Potential safety issues and adverse events (AEs) were collected. Univariable and multivariable logistic regressions were performed for variables predicting clinical response. One hundred and twelve patients with psoriasis were included. PASI90 response was achieved by 17.86% of patients at week 4, 72.22% at week 16, 91.0% at week 28 and 95.24% at week 52 (as observed analysis). No associations between the considered variables and the efficacy endpoints were retrieved, influence of variables such as Body Mass Index (BMI), baseline PASI or previous biologics were not shown. No serious safety issues or discontinuations related to adverse events were reported. Risankizumab showed high efficacy and a favorable safety profile, regardless of patient- and disease-related factors.
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/35
English
efficacy
interleukin-23
psoriasis
real-life
risankizumab
safety
Antibodies, Monoclonal
Humans
Retrospective Studies
Severity of Illness Index
Treatment Outcome
Psoriasis
Caldarola, G., Zangrilli, A., Bernardini, N., Bavetta, M., De Simone, C., Graceffa, D., et al. (2022). Risankizumab for the treatment of moderate-to-severe psoriasis: A multicenter, retrospective, 1 year real-life study. DERMATOLOGIC THERAPY, 35(6), e15489 [10.1111/dth.15489].
Caldarola, G; Zangrilli, A; Bernardini, N; Bavetta, M; De Simone, C; Graceffa, D; Bonifati, C; Faleri, S; Giordano, D; Mariani, M; Micheli, A; Moretta, G; Pagnanelli, G; Panasiti, V; Provini, A; Richetta, A; Peris, K; Bianchi, L
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
Risankizumab for the treatment of moderate‐to‐severe psoriasis A multicenter.pdf

solo utenti autorizzati

Licenza: Copyright dell'editore
Dimensione 1.29 MB
Formato Adobe PDF
1.29 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2108/304582
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 0
social impact